Generic Medicine Info
Indications and Dosage
Susceptible infections
Adult: 6-12 g/day in 2 divided doses.
Child: 100 mg/kg/day.
Porphyria; severe renal or hepatic failure; blood disorders; hypersensitivity to sulfonamides; SLE. Pregnancy (prior to delivery). Lactation. Infants within 1-2 mth of birth.
Special Precautions
Adequate fluid intake is necessary to reduce the risk of crystalluria. Discontinue immediately if rash appears. Renal or hepatic impairment; asthma or history of allergy; elderly. G6PD deficiency.
Adverse Reactions
GI effects, hypersensitivity reactions, nephrotoxic reactions, hepatic disorders, CV effects, hypoglycaemia, hypothyroidism, neurological reactions. Pseudomembranous colitis; jaundice and kernicterus in the newborn.
Potentially Fatal: Toxic epidermal necrolysis, Stevens-Johnson syndrome, anaphylaxis, blood dyscrasias.
Drug Interactions
Action antagonised by PABA and procaine group of local anaesthetics. Potentiates oral anticoagulants, methotrexate and phenytoin. Increased risk of crystalluria with compounds that render urine acidic.
Lab Interference
May interfere with diagnostic tests for urea, creatinine and urobilinogen.
Description: Sulfaguanidine is a sulfonamide with properties similar to those of sulfamethoxazole. Sulfonamides have a similar structure to para-aminobenzoic acid (PABA) and interfere with the synthesis of nucleic acid in sensitive microorganisms by blocking the coversion of PABA to the co-enzyme dihydrofolic acid, a reduced form of folic acid. Their actions are primarily bacteriostatic, although bactericidal effects are exerted where concentrations of thymine are low in the surrounding medium.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Sulfaguanidine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in